Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what discussions NHS England has had with (a) breast cancer charities and (b) patient groups on the introduction of the biosimilars of Herceptin, Trastuzumab.

NHS England is working closely with the Cancer Vanguard and the Chemotherapy Clinical Reference Group to ensure all stakeholders, including charities and patient groups, are involved with the implementation of biosimilar trastuzumab.